RenovoRx (RNXT) Stock Research

Today

RenovoRx completes enrollment in TIGeR-PaC trial

RNXT

8:46 AM

Over a week ago

RenovoRx announces FDA Orphan Drug Designation for oxaliplatin

RNXT

May 28, 9:13 AM

RenovoRx announces pharmacokinetic data using TAMP platform

RNXT

May 26, 8:48 AM

RenovoRx sees FY26 revenue $3M-$4M, consensus $3.24M

RNXT

May 14, 4:17 PM

RenovoRx reports Q1 adjusted EPS (8c), consensus (8c)

RNXT

May 14, 4:16 PM

RenovoRx files to sell 8.44M shares of common stock for holders

RNXT

Apr 16, 5:11 PM

RenovoRx secures Japanese patent allowance for targeted drug-delivery

RNXT

Apr 8, 9:14 AM

RenovoRx's TIGeR-PaC Phase III trial surpasses 100 randomized patients

RNXT

Mar 26, 9:18 AM

RenovoRx prices 10.6M shares at 93.8c in private placement

RNXT

Mar 18, 8:44 AM

RenovoRx advances RenovoCath adoption at U.S. cancer centers

RNXT

Feb 27, 8:41 AM

RenovoRx announces acceptance of clinical data abstract at 2026 SIR

RNXT

Feb 26, 8:39 AM

RenovoRx establishes RenovoCath Medical Advisory Board

RNXT

Feb 10, 8:40 AM

RenovoRx appoints Voll as Chief Financial Officer

RNXT

Feb 5, 8:39 AM

RenovoRx announces new clinical data on TAMP therapy platform

RNXT

Feb 4, 8:32 AM

RenovoRx initiated with bullish view at JonesResearch, here's why

RNXT

Jan 29, 4:20 PM

RenovoRx expands RenovoCath commercial adoption to nine cancer centers

RNXT

Jan 20, 8:38 AM

RenovoRx to announce new clinical data from Phase III TIGeR-PaC trial

RNXT

Jan 8, 8:51 AM

RenovoRx files $50M mixed securities shelf

RNXT

Nov 14, 4:37 PM

RenovoRx price target lowered by 50c at Alliance Global, here's why

RNXT

Nov 14, 2:15 PM

RenovoRx reports Q3 EPS (8c), two estimates (8c)

RNXT

Nov 13, 4:42 PM

RenovoRx appoints Timothy Donahue to Strategic Advisory Board

RNXT

Nov 6, 8:46 AM

RenovoRx expands Scientific Advisory Board with appointment of Baere

RNXT

Oct 9, 8:44 AM

RenovoRx announces first patient procedure completed in PanTheR study

RNXT

Sep 25, 8:38 AM

No more stories